Kornimate/medical-research-clean huggingface dataset:
the effect of switching the h1-antagonist clemastine to cetirizine in premedication regimens during paclitaxel treatment

Conditions: Solid Tumor

Summary: in this study the effect of substituting clemastine iv to cetirizine po on the occurence of hypersensitivity reactions during paclitaxel chemotherapy will be investigated.

this is a single arm before-after study with a historic control cohort to evaluate the effect of a policy change (i.e. substitution of clemastine iv for cetirizine po) regarding the premedication scheme on the incidence of hsr during paclitaxel based chemotherapy.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * planned treatment with regular paclitaxel-based chemotherapy for any indication and with any dose exclusion criteria: * prior treatment with a paclitaxel-based regimen; * inability to orally ingest cetirizine

Keywords: paclitaxel allergic reaction hsr chemotherapy premedication cancer oncology
tracking of upper limb sensory and motor recovery in asian stroke survivors

Conditions: Stroke

Summary: as singapore's population is aging rapidly, the incidence rate of stroke has been increasing in the past years. rehabilitation is essential for the resumption of daily activities, and with the appropriate care, it is possible for stroke-survivors to regain most of their functions. hence, this study aims to better understand upper limb recovery covering different stages post-stroke in a representative cohort of asian adults

stroke is a leading contributor to disability in singapore, partially driven by a reduced ability to use the upper limb in their daily lives. reduced upper limb use commonly results from a variety of impairments such as motor, sensory and cognitive impairments. the aim of this longitudinal and observational study is to gather a rich multi-modal database on the time-course of upper limb recovery in a representative cohort after stroke and characterise the relationship between upper limb recovery, common post-stroke impairments and quality of life.

Eligibility criteria:
inclusion criteria: 1. stroke confirmed by neurologists, neurosurgeons and brain imaging (ct, ct angiogram, mri, mr angiogram) 2. first ever confirmed stroke 3. asian ethnicity 4. age 21-90 years 5. montreal cognitive assessment (moca) scores 21/30 and above 6. admission to rehabilitation ward is within 8 weeks of stroke onset exclusion criteria: 1. recurrent stroke or transient ischaemic attack (tia) 2. upper limb impairment not related to stroke: e.g., subarachnoid haemorrhage, traumatic brain injury or brain tumours 3. bilateral upper limb impairment. 4. uncontrolled medical conditions such as hypertension, hypotension, diabetes mellitus, unstable angina, cardiac failure or sepsis will be excluded. 5. active fractures or arthritis of upper limb joints/bones 6. visual analogue scale (vas) pain \> 5/10 7. moca \< 21/30 8. severe behavioural disturbance or agitation or epilepsy or untreated depression 9. life expectancy \< 6 months 10. end organ failures on replacements (renal dialysis or renal replacement therapies) 11. minimally responsive or unresponsive awareness (vegetative) states 12. pregnancy or lactation states 13. admission to rehab ward later than 8 weeks post-stroke 14. (for tms assessments only) history of epilepsy or seizures, or cranial surgeries, or have metal implants in body or head, or have implanted electronics, or have metallic valve, or skull fracture or brain injury, or head or brain surgeries.
nerve transfer for finger sensory reconstruction with dorsal branch of the digital nerve

Conditions: Sensory Restoration of the Reconstructed Finger Pulps; Cold Intolerance of the Reconstructed Finger; Pain of the Reconstructed Finger

Summary: a proper digital nerve (pdn) defect causes partial or complete sensory loss of the finger pulp, which results in functional disability.the dorsal branch of the pdn can be transferred for reconstruction of such nerve defects.in this study, the investigators modified the lesavoy et al' technique and evaluated the efficacy of dorsal sensory branch transfer for pdn defects. for comparison, the investigators collected a consecutive series of 32 patients with finger pdn defects treated using a traditional sural nerve graft from february 2005 to october 2008.


Eligibility criteria:
inclusion criteria: 1. finger pdn defects proximal to the proximal interphalangeal joint 2. single or two pdn defects 3. pdn defects longer than 1 cm. exclusion criteria: 1. pdn defects less than 1 cm 2. concomitant injuries to the multiple dorsal sensory branches that preclude their use as nerve donor sites 3. thumb pdn defects.

Keywords: defect dorsal branch of the proper digital nerve proper digital nerve nerve transfer finger sensory reconstruction
reducing the risk of phlebitis from peripheral venous catheter

Conditions: Phlebitis

Summary: nurses frequently use peripheral venous catheters in hospitals to provide medications and fluids for therapeutic and diagnostic purposes. peripheral venous catheter use brought various problems, including phlebitis, infiltration, extravasation, ecchymosis, thrombophlebitis, and embolism, in addition to being a regularly utilized nursing practice. the literature used techniques like heat application, fist clenching, and proximal massage to lower the risk of thrombophlebitis and associated problems.

between october and november 2022, individuals who received orthopedic care at a state hospital and had peripheral venous catheters participated in the trial as a randomized controlled experimental study. the control group received routine nursing care, while the experimental group received proximal massage and palm fist exercises. the numbers used to identify the control and experimental groups were drawn at random from a table of random numbers, and each group had 36 patients. the researcher used the "patient information form," "plebitis risk scale due to peripheral venous catheter," and "plebitis diagnostic scale" to collect data using in-person interviews and observational methods. the p value for statistical significance is p\<0.05. proximal massage: for a total of 5 to 10 minutes, twice daily for 4 days, between 30 seconds- 1 minute in sessions of approximately 20 strokes, a light massage is administered utilizing the palm surfaces of the fingers. under the researcher's supervision, participants in the activity known as fist clenching squeeze a soft palm ball 20 times in each of twice a day for four days, lasting between 30 seconds - 1 minute.

Eligibility criteria:
inclusion criteria: * patients who volunteered to participate in the study, * who are over 18 years old, * having no barriers to written and verbal communication in turkish, * iv treatment was applied during the hospitalization period and iv treatment was recently started, * patients with iv cannula in the upper extremity * in the last six months before hospitalization, iv treatment was not applied, * a maximum of 2 iv attempts should be made on a patient. * patients without chronic dermatological and/or vascular disease. exclusion criteria: * patients who did not volunteer to participate in the study, unconscious patients, * iv attempts were made to the same patient more than 4 times in total, * patients with iv cannula in the lower extremity.

Keywords: phlebitis peripheric venous catheter nursıng care palm fisting proximal massage
intracavernosal injection of papaverine/verapamil versus papaverine/phentolamine in erectile dysfunction

Conditions: Erectile Dysfunction

Summary: introduction: erectile dysfunction is a common condition with a significant effect on quality of life. verapamil is calcium channel blocker of the phenyl alkylamine class which relaxes the tone of the smooth muscles lining blood vessels, leading to their dilatation.

objective: evaluating the effect of intracavernosal injection of (papaverine + verapamil) and comparing it with (papaverine + phentolamine) in patients with erectile dysfunction. patients and methods: each one of the 20 erectile dysfunction patients was subjected to intracavernosal injection with (30mg papaverine + 1mg phentolamine), where penile duplex \& clinical evaluation was carried out followed by a wash out interval of 2 weeks after which each patient was subjected to the exact previous procedures using (30 mg papaverine + 5 mg verapamil). keywords: erectile dysfunction - intracavernosal injection - penile duplex - phentolamine - verapamil.

Eligibility criteria:
inclusion criteria: * married male patients suffering from erectile dysfunction and scheduled for intracavernosal injection. exclusion criteria: * responders to pde5-inhibitors; congenital or acquired penile anomalies; uncontrolled medical conditions or known hypersensitivity to verapamil; peyronie's disease and any known bleeding or coagulation disorders.
assessment of stroke volume in shock using echocardiography versus bioreactive impedance

Conditions: Shock; Critical Illness

Summary: this study aims to evaluate the correlation between stroke volume measurements obtained by transthoracic echocardiography and bioreactance-based noninvasive cardiac output monitoring. the primary objective is to assess the level of agreement between these two modalities in critically ill patients.

in this prospective observational study, patients presenting with clinical signs of shock will be enrolled after obtaining informed consent. stroke volume (sv) will be measured using both transthoracic echocardiography and bioreactance-based noninvasive cardiac output monitoring (cheetah nicom). sv will be recorded before and after passive leg raising (plr) to evaluate the correlation between the two methods in terms of absolute values and directional changes (increase or decrease). no therapeutic intervention will be performed as part of the study; all clinical decisions will remain under the discretion of the treating medical team.

Eligibility criteria:
inclusion criteria * age ≥ 18 years * clinical diagnosis of shock as determined by the treating icu physician (e.g., hypotension requiring vasopressors or evidence of end-organ hypoperfusion) * able to obtain informed consent from the patient or a legally authorized representative * enrollment within 24 hours of icu admission exclusion criteria: * pregnancy * known severe aortic valve disease or dynamic left ventricular outflow tract obstruction * morbid obesity (bmi \> 40) that precludes accurate echocardiographic imaging presence of cardiac arrhythmias (e.g., atrial fibrillation with rapid ventricular response) affecting stroke volume measurements * implanted cardiac assist devices (e.g., lvad, pacemaker dependency) * imminent death or decision for comfort care only

Keywords: cheeta nicom bioreactance transthoracic echocardiography passive leg raising stroke volume shock assssment noninvasive cardiac output monitoring
french observatory of acute heart failure

Conditions: Acute Heart Failure

Summary: during the last decade, progress has been made in the management of heart failure. however, the changing characteristics of patients and practices in the "real world" and their impact on the prognosis of patients admitted for acute heart failure remain poorly studied. 2000 consecutive patients recruited in a single day in hospitals volunteered to participate in the cohort during a day dedicated.

the total duration of recruitment is one day (date to be set soon by the executive committee): all patients hospitalized, and whatever their date of admission with the diagnosis of heart failure will be selected for the study. information on each hospital stay will be obtained at baseline and at the end of the hospitalization by the hospital teams. a telephone follow-up will be conducted at 3 months among survivors and / or their doctor by cras dedicated to the french society of cardiology.

Eligibility criteria:
inclusion criteria: 1. male or female age (e) over 18 years 2. inpatient, whatever the mode of initial admission with acute heart failure (de novo heart failure or decompensation of chronic heart failure) regardless of severity, corresponding to one of the following clinical situations (clinical criteria in appendix 1): * pulmonary edema, hypertensive or not * congestive heart failure (pulmonary congestion and peripheral edema) * cardiogenic shock * insufficient high output cardiac 3. patients who agreed to participate in the study 4. isolated right heart failure exclusion criteria: 1. expressed refusal to participate in the study 2. hospitalization scheduled for review 3. background surgery (immediate postoperative period) 4. diagnosis of acute heart failure reversed in favor of an alternative diagnosis before discharge from hospital

Keywords: acute heart failure
a phase2 of a-101 topical solution in subjects with common warts

Conditions: Common Wart

Summary: the primary objective of this study is to evaluate the effectiveness of a-101 compared to vehicle when applied to 1 common target wart on the trunk or extremities.

the primary objective of this study is to evaluate the effectiveness of a-101 compared to vehicle when applied to 1 common target wart on the trunk or extremities. the secondary objectives of this study are to evaluate the clinical effect of a-101 when applied to all treated warts (target warts plus non-target warts), duration of response in all treated warts (target warts plus non-target warts), and safety of a-101.

Eligibility criteria:
inclusion criteria: * subject is able to comprehend and is willing to sign an informed consent/assent for participation in this study. * male or female ≥ 8 years old. * subject has a clinical diagnosis of common warts. * subject chemistry and complete blood count results are within normal limits. if any of the laboratory values are outside normal range, the treating investigator must assess the value/s as not clinically significant and document this in the subject's medical chart in order for the subject to be eligible for randomization. * women of childbearing potential (wocbp) must have a negative urine pregnancy test within 14 days of the first application of study drug and agree to use an active method of birth control for the duration of the study. * subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair the evaluation of any target and non-target warts or which exposes the subject to an unacceptable risk by study participation. * subject is willing and able to follow all study instructions and to attend all study visits. exclusion criteria: * subject has clinically atypical warts on the trunk or extremities. * subject is immunocompromised (e.g, due to chemotherapy, systemic steroids, genetic immunodeficiency, transplant status, etc.) * subject has a history of human immunodeficiency virus (hiv) infection * subject has had any human papilloma virus (hpv) vaccine within 1 year prior to visit 1 * subject has a history of sensitivity to any of the ingredients in the study medications. * subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations. * participation in another therapeutic investigational drug trial in which administration of an investigational study medication occurred with 30 days prior to visit 1.
exopulse mollii suit, motor function & multiple sclerosis

Conditions: Multiple Sclerosis

Summary: spasticity is a frequent and debilitating symptom in patients with multiple sclerosis (ms). it can alter the patients' balance, mobility, as well as their quality of life. the available therapeutic strategies for treating spasticity and related symptoms are usually faced with limited efficacy and numerous side effects. for these reasons, non invasive stimulation techniques, namely transcutaneous stimulation by means of exopulse mollii suit, might be of help in this context.

the investigators designed a randomized crossover, sham-controlled, double blind trial to demonstrate the improvement of motor functions and ms related symptoms following a single session of "active" versus "sham" exopulse mollii suit. a 2-week washout period should be enough to prevent a potential carry over effect. two weeks after the end of this phase (phase 1), a second phase of this trial, an open label phase, will be proposed for all patients to understand the effects of exopulse mollii suit employed over four weeks (a session every other day for a total of 14 sessions) on ms related symptoms.

Eligibility criteria:
inclusion criteria: * definite ms diagnosis according to the 2017 mcdonald criteria since at least one month. * age between 18 and 75 years. * ability to walk freely or with the need of support (expanded disability status scale score (edss) \< 7). * being free of relapses in the last three months. * being french speaker, able to understand verbal instructions, and affiliated to the national health insurance (sécurité sociale). * having spasticity with a score of at least 1+ on the mas. * having a bbs score ≤46 associated in the literature with a risk of fall exclusion criteria: * being included in another research protocol during the study period. * inability to undergo medical monitoring for the study purposes due to geographical or social reasons. * having a cardiac stimulator, a ventriculoperitoneal shunt, an intrathecal baclofen pump or other contraindications to using exopulse mollii suit. * being pregnant. * having a change in their pharmacological therapy in the last three months. * suffering from other somatic or neuropsychiatric diagnoses (e.g., arrhythmias, uncontrolled epilepsy, diseases causing osteoarticular and muscular pain). * having a body mass index above 35 kg/m2. * in case of the introduction of a medical device other than exopulse mollii suit during the study period * patients under juridical protection (" mesure de protection judiciare : tutelle, curatelle, sauvegarde de justice ") * prisoners.

Keywords: spasticity motor functions quality of life
reference intervals of the semg of the pelvic floor in healthy female

Conditions: Pelvic Floor

Summary: this study is a multi-center survey of surface electromyography (semg) of pelvic floor muscles in healthy female. the aim of the study is to get the reference interval of normal pelvic floor semg from chinese women.

pelvic floor dysfunction is a group of diseases caused by the damage of pelvic floor supporting structure. pelvic floor muscles play an important role in the maintenance of pelvic floor function. surface electromyography (semg) has been widely used to evaluate the function of pelvic floor muscles. the semg tests, which include pretest and posttest resting amplitude (µv), as well as phasic, tonic and endurance contractile amplitude (µv), are performed using vishee neuro-muscle stimulator (myotrac infiniti, model sa9800, thought technology ltd., montreal, canada), following the glazer protocols. a pear-shaped vaginal probe (serial number dys180610, type vet-a, produced by nanjing vishee medical technology, ltd.) is placed into the vagina when semg tests are performed. this is a cross-sectional survey. the reference intervals of pelvic floor semg in healthy female are evaluated.

Eligibility criteria:
inclusion criteria: * a. having sex life and tolerable to vaginal examination b. there were no symptoms related to pelvic floor dysfunction; c. the modified oxford grading system was 4 or 5; d. no birth or 2 years after the last delivery; exclusion criteria: * a. duration of pregnancy and lactation; b. within 2 years after delivery; c. acute inflammation of vagina or discomfort of vagina; d. history of pelvic floor dysfunction: leakage of urine in the past 1 month when coughing / sneezing / lifting; leakage of urine in the past 1 month when urgency fecal incontinence in the past 1 month; usually have a bulge or something falling out that can be seen or felt in vaginal area; pain in the abdomen or lumbosacral and buttocks below the navel for more than 6 months; e. history of radical pelvic surgery (cervical cancer, rectal cancer, bladder cancer, etc.); f. history of hysterectomy and subtotal hysterectomy; g. history of pelvic floor surgery (anti-incontinence and prolapse surgery); h. history of pelvic radiotherapy; i. nervous system diseases that significantly affect muscle function; j. those who can't cooperate with pelvic floor contraction
evaluation of 3d simulation and planning of left atrial appendage occlusion based on 3d echocardiography

Conditions: ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION

Summary: this study aims to compare a semi-automatic 3d echocardiography-based left atrial appendix occlusion procedure planning with feops, with other imaging modalities for evaluating the left atrial appendage dimensions and device prediction (sizing, deformation) pre-left atrial appendix occlusion , including the current "gold standard", ct- based feops heartguidetm left atrial appendix occlusion procedure planning. a number of pre-specified endpoints are defined for analyzing this new approach.

first, the investigator will compare dimensions of left atrial appendix ostium and device landing zone, and the predicted device size and deformation based on the gold standard (ct-based analysis by feops heartguidetm, with ostium and landing zone dimensions, predicted device size (based on the device sizing chart) and device deformation predicted by feops analysis of the 3d echo images. complementary, dimensions and device size prediction derived from 3d echo-derived feops analysis, will also be compared to measurements and device size prediction obtained from pre-procedural ct images and the 2d per-procedural transesophageal echocardiographic evaluation. secondly, the process of echo image analysis by feops will be tested by evaluating the percentage of cases where feops anatomical analysis is successful in providing a complete report. based on the acquired 3d echo data, case processing is considered successful if ostium and landing zone diameters (minimum, maximum, mean and perimeter-based diameter), and device sizing, together with predicted device deformation, can be reported. the number of cases where only partial reporting is possible, as well the cases where no reporting is feasible, will also be recorded. if case analysis is not successful, the reason for failure will be reported.

Eligibility criteria:
inclusion criteria: * patients planned for laao with an amplatzer amulet left atrial appendage occluder (abbott medical) * clinical indication (in line with currently accepted indications and national reimbursement criteria) * inclusion in 2 experienced belgian laao centers (brussels and genk) exclusion criteria: * contra-indication for contrast (including contrast allergy and renal failure), * contra-indication for radiation exposure (e.g. pregnancy) * inability by feops to analyze ct images and provide a report